CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $55.82M, above the global median of $18.73M
- FinancialsAltman Z-Score 2.07: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.23BCNY929.98M · vs all stocks (USD)
Revenue (TTM)
2.56BCNY381.42M · vs all stocks (USD)
Profit Margin
-4.93%Beta
0.2550xvs all stocks
52-Week Change
-20.35%vs all stocks
Market Capitalization
6.23BCNY929.98M · vs all stocks (USD)
Enterprise Value
6.98BCNY1.04B · vs all stocks (USD)
Price to Sales (TTM)
2.43xPrice to Book (MRQ)
1.92xEnterprise to Revenue
2.73xEnterprise to EBITDA
40.74xGross Margin
33.68%Profit Margin
-4.93%Operating Margin
13.02%Return on Assets (TTM)
0.49%Return on Equity (TTM)
-3.94%Revenue (TTM)
2.56BCNY381.42M · vs all stocks (USD)
Revenue per Share (TTM)
1.82CNYUpdated Sep 19, 2026Quarterly Revenue Growth
-53.50%Gross Profit (TTM)
1.05BCNY156.80M · vs all stocks (USD)
EBITDA (TTM)
227.61MCNY33.95M · vs all stocks (USD)
Net Income (TTM)
-126.17MCNY-18.82M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-93.40%Operating Cash Flow (TTM)
572.01MCNY85.32M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
374.23MCNY55.82M · vs all stocks (USD)
5-Year Average Dividend Yield
1.12%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
19.28MCNYFY2025 · Dec 31, 2025Revenue
3.05BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.60BCNYFY2025 · Dec 31, 2025Gross Profit
1.44BCNYFY2025 · Dec 31, 2025Operating Income
227.20MCNY33.89M · vs all stocks (USD)
Pre-tax Income
40.47MCNYFY2025 · Dec 31, 2025Income Tax Expense
143.60MCNYFY2025 · Dec 31, 2025Net Income
-103.12MCNYFY2025 · Dec 31, 2025EBIT
44.16MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
227.61MCNYFY2025 · Dec 31, 2025Research & Development
17.96MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
716.64MCNYFY2025 · Dec 31, 2025Other Operating Expenses
43.94MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
634.49KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.69MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0800CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.30BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.30BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-103.12MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.24MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
786.56MCNYFY2025 · Dec 31, 2025Free Cash Flow
685.20MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
340.89MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-103.12MCNYFY2025 · Dec 31, 2025Other Non-cash Items
69.38MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
382.70MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
437.61MCNYFY2025 · Dec 31, 2025Capital Expenditures
-101.36MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-10.00MCNYFY2025 · Dec 31, 2025Sale of Investments
16.47MCNYFY2025 · Dec 31, 2025Other Investing Activity
108.70KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-94.78MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.17BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.72BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-62.48MCNYFY2025 · Dec 31, 2025Other Financing Charges
-17.33MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-636.44MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.40BSharesUpdated Sep 19, 2026Float Shares
1.12BSharesUpdated Sep 19, 2026% Held by Insiders
32.76%vs all stocks
% Held by Institutions
0.43%vs all stocks
Total Cash (MRQ)
181.21MCNY27.03M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1330CNYUpdated Sep 19, 2026Total Debt (MRQ)
1.06BCNY158.47M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3320xCurrent Ratio (MRQ)
0.9740xBook Value per Share (MRQ)
2.33CNYUpdated Sep 19, 2026Total Assets
6.20BCNY924.42M · vs all stocks (USD)
Total Current Assets
2.72BCNYFY2025 · Dec 31, 2025Total Liabilities
3.02BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.47BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
223.14MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.80BCNYFY2025 · Dec 31, 2025Cash
348.71MCNYFY2025 · Dec 31, 2025Cash Equivalents
6.09MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
354.80MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.29BCNYFY2025 · Dec 31, 2025Inventory
665.85MCNYFY2025 · Dec 31, 2025Accounts Payable
764.77MCNYFY2025 · Dec 31, 2025Short-term Debt
1.08BCNYFY2025 · Dec 31, 2025Other Current Liabilities
51.93MCNYFY2025 · Dec 31, 2025Long-term Debt
152.59MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.40BCNYFY2025 · Dec 31, 2025Retained Earnings
1.49BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.17BCNY473.55M · vs all stocks (USD)
Treasury Stock
219.59MCNYFY2025 · Dec 31, 202552-Week Low
4.08CNYUpdated Sep 19, 202652-Week High
6.43CNYUpdated Sep 19, 202652-Week Change
-20.35%vs all stocks
Beta
0.2550xvs all stocks
50-Day MA
4.57CNYUpdated Sep 19, 2026200-Day MA
4.68CNYUpdated Sep 19, 2026Avg 10-Day Volume
8.46MSharesUpdated Sep 19, 2026Avg 30-Day Volume
7.91MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
-0.1000CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.07: grey zoneSignificant
Altman Z-Score: 2.07
High earnings qualityNotable
Earnings Quality Score: 0.93
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $55.82M, above the global median of $18.73MNotable
Levered free cash flow (USD): 55,820,760.146Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medincell SA
Tier 1ProductionApproval-Gated PipelineRule
R&G Pharmastudies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alumis Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Jade Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bioventus Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Beijing Tong Ren Tang Chinese Medicine Company Ltd.
Tier 1ProductionApproval-Gated PipelineRule